131 results about "Colitis" patented technology

The present application relates to the field of biotechnology, and more particularly to the application of a functional component of peony pollen in the preparation of anti-inflammatory products. The peony pollen has a significant remission effect on the mouse ulcerative colitis model, and plays a remission effect on ulcerative colitis by inhibiting colon shortening, repairing intestinal barrier and crypt structure, etc., greatly expanding the medicinal value of peony pollen.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The application belongs to the technical field of new application of microorganisms, and particularly relates to an enterobacter and application of the enterobacter in improving inflammatory bowel disease. The strain is named LS-68, is preserved in the China General Microbiological Culture Collection Center, has a preservation date of October 28, 2024, and has a preservation number of CGMCC NO.32368. The strain has the ability of group movement, has strong adaptability to the intestinal environment, well tolerates the acidity of gastric juice, is sensitive to a plurality of commonly used antibiotics, and has a good improvement effect on colitis.

The application discloses sodium alginate-kelp polysaccharide-ganoderic acid D nanoparticles for targeted treatment of ulcerative colitis and a preparation method and application thereof. Raw materials of the nanoparticles include sodium alginate, kelp polysaccharide and ganoderic acid D with a mass ratio of 20-30:2-5:8-12. The sodium alginate-kelp polysaccharide-ganoderic acid D nanoparticles are prepared by taking sodium alginate gel as a carrier and loading kelp polysaccharide and ganoderic acid D in the carrier, and the nanoparticles are used for preventing and / or relieving ulcerative colitis, can have antioxidant effect, target regulation of intestinal barrier function, reduction of inflammatory reaction and improvement of intestinal health, and provide a new method for ulcerative colitis.

This invention relates to the field of ulcerative colitis (UC) prediction technology, specifically to an UC prediction model, its construction method, and a prediction kit. The risk score for each sample is calculated as follows: 68.798 – 11.031 * HMGCS2 relative expression level – 46.586 * GCNT2 relative expression level + 20.391 * B4GALNT2 relative expression level + 5.719 * NAT8B relative expression level + 26.562 * LPCAT1 relative expression level + 17.042 * PPARGC1A relative expression level – 10.500 * ACSS2 relative expression level + 3.110 * PDK2 relative expression level – 77.421 * HADHA relative expression level. A risk score less than zero is defined as non-ulcerative colitis, and a risk score greater than zero is defined as ulcerative colitis. This application provides a model for diagnosing ulcerative colitis, applicable to the rapid diagnosis of clinical samples, providing objective and quantitative criteria for UC diagnosis, and solving the problems of insufficient sensitivity and specificity of traditional diagnostic methods.

This application discloses the application of dasabuvir as a TRPV4 inhibitor in improving diseases caused by increased TRPV4 expression or enhanced activity, particularly ulcerative colitis. Specifically, it relates to the biomedical field. Dasabuvir is a novel TRPV4 inhibitor that can improve symptoms in a DSS-induced mouse ulcerative colitis model and is suitable for use in TRPV4 inhibitor drugs and ulcerative colitis drugs. In HEK-293 cells overexpressing TRPV4, dasabuvir can dose-dependently inhibit the increase in intracellular calcium ion concentration induced by the TRPV4-specific agonist GSK1016790A within a concentration range of 0.03-30 μM, with an IC50 concentration of [missing information]. 50 At a concentration of 0.27 μM, Dasabuvir is a highly active TRPV4 inhibitor. In a DSS-induced ulcerative colitis model, Dasabuvir can improve weight loss, reduce the disease activity index, alleviate colonic shortening, reduce histopathological changes, and inhibit the expression of inflammatory factors, thus improving ulcerative colitis.

In some aspects, a method, a system, or a non-transitory computer-readable storage medium are described for training one or more models to predict ulcerative colitis (UC) severity based on human-interpretable image features extracted from a whole-slide image, including acts of accessing a plurality of annotated whole-slide images associated with a plurality of UC patients, wherein each of the plurality of annotated whole-slide images includes at least one annotation describing a cell-type label or a tissue-type segmentation for a portion of the whole-slide image, extracting a plurality of human-interpretable image features based on cell-type labels and tissue-type segmentations associated with the plurality of annotated whole-slide images, training a statistical model based on the plurality of human-interpretable image features to predict the UC severity for a whole-slide image, and storing the trained model on at least one storage device.

This invention provides a controlled-release pharmaceutical composition containing indigo naturalis or its main active ingredient, a method for its preparation, and its application. The controlled-release pharmaceutical composition comprises microspheres, each microsphere containing the active ingredient and one or more pharmaceutically acceptable excipients. The active ingredient includes indigo naturalis, indigo, indirubin, or any combination thereof; the microspheres are coated with an enteric outer layer. The controlled-release pharmaceutical composition provided by this invention can alleviate the symptoms of inflammatory bowel diseases, especially ulcerative colitis, and can reduce or avoid the endocytosis of the active ingredient by intestinal macrophages, thereby reducing the impact on the patient's liver. It exhibits good stability, and the controlled-release pharmaceutical composition of this invention reduces side effects while maintaining therapeutic efficacy.

This invention discloses an isoflavone compound, its preparation method, and its applications. The compounds are derived by directional esterification modification of all phenolic hydroxyl groups with allyloxycarbonyl chloride, o-chlorobenzoyl chloride, or cinnamoyl chloride, using 4',7-dihydroxyisoflavone or 4',5,7-trihydroxyisoflavone as the parent nucleus. The invention also provides a mild and efficient preparation method for these compounds and confirms their significant anti-inflammatory pharmacological activity. Pharmacological studies show that compounds B and E, in particular, exhibit excellent in vitro and in vivo anti-inflammatory activity, with compound E showing superior activity compared to the positive control drug dexamethasone. These compounds can be used to prepare drugs for treating inflammatory diseases such as pneumonia and colitis.

This invention discloses the application of berberine-loaded herbal carbon dots in the preparation of drugs for treating ulcerative colitis. The BLCDs of this invention exert their therapeutic effect through a dual synergistic mechanism: directly scavenging reactive oxygen species through surface oxygen-containing functional groups, and simultaneously inhibiting the NLRP3 inflammatory pathway and downstream pro-inflammatory factors by promoting IL-10 expression. In a DSS-induced ulcerative colitis mouse model, BLCDs showed superior efficacy compared to the positive control drug 5-ASA and its single component, significantly improving intestinal inflammation, oxidative stress, and barrier dysfunction. Their therapeutic advantage stems from the intestinal retention effect conferred by their larger particle size, as well as their regulatory effects on intestinal flora and metabolites, particularly by inhibiting Klebsiella to reduce TMAO production, thereby activating the multi-cascade regulatory network of IL-10.

Pharmaceutical compositions comprising bile acid sequestrants, their use in treating bile acid malabsorption, and associated conditions such as bile acid diarrhea and colitis are described herein. Methods for treating bile acid malabsorption and associated conditions are also described.

This disclosure relates to compounds of formula I (wherein X and R1-R4, n and m have the meanings set forth herein) and pharmaceutically acceptable salts thereof. Compounds of formula I exhibit GPR183 antagonist activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases for which GPR183 antagonists have been shown to be useful, such as chronic pain, e.g., osteoarthritis, chronic low back pain, neuropathic pain, and immune system disorders, e.g., inflammatory bowel diseases such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, e.g., asthma, and psoriasis. TIFF2026522963000085.tif2570

The application relates to the technical field of medicines, in particular to application of N-acetylneuraminic acid in preparation of medicines for preventing and / or treating ulcerative colitis. The application finds that N-acetylneuraminic acid can effectively prevent or treat ulcerative colitis and promote tissue repair by regulating macrophage metabolism, inhibiting glycolysis pathways and M1 type polarization, and simultaneously repairing intestinal mucosal barrier, thereby providing a safe, simple and clear mechanism of action new treatment strategy for clinic.

This invention provides an HDAC6 inhibitor, its preparation method, and its use in anti-inflammatory and ulcerative colitis treatment. By linking an alkaloid structure with anti-inflammatory activity to the hydroxamic acid group of the HDAC6 inhibitor, a series of novel compounds containing alkaloid structures and exhibiting anti-ulcerative colitis activity have been developed. Experimental data show that the above compounds exhibit good inhibitory effects on HDAC6 at the enzyme level and can be used to prepare drugs for the prevention or treatment of ulcerative colitis.

The application belongs to the technical field of microorganisms, and discloses Lactobacillus fermentum (L.f) LFSJ001 and application thereof in preparation of products for preventing or treating ulcerative colitis. The Lactobacillus fermentum LFSJ001 is independently isolated and identified. It is found through the use of DSS to construct a mouse colitis model that the Lactobacillus fermentum LFSJ001 combined with 5-Aminosalicylic Acid (5-ASA) can enhance the improvement of 5-ASA on the symptoms of colitis, including multiple indexes such as disease activity index, colon injury, and spleen index. It can be seen that the Lactobacillus fermentum LFSJ001 can be used as a combined drug of 5-ASA, enhance the efficacy of 5-ASA, inhibit the occurrence and development of ulcerative colitis, and improve the intestinal barrier. The application provides a new diagnosis and treatment direction and strategy for the prevention and treatment of ulcerative colitis.

This invention belongs to the field of microbial technology, specifically disclosing a probiotic composition and its application. The probiotic composition provided by this invention includes at least two of the following: prebiotics, vitamin K, and zinc, as well as *Bifidobacterium longum* subsp. infantis i18. The probiotic composition provided by this invention can not only effectively promote the growth and development of premature mice, but also optimize the intestinal flora structure and promote intestinal development in premature infants by reducing the abundance of harmful bacteria and increasing the relative abundance of beneficial bacteria; simultaneously, it can downregulate the levels of pro-inflammatory factors TNF-α and IL-6, reducing intestinal inflammation and lowering the risk of necrotizing enterocolitis in premature infants. This invention can be applied to the preparation of products that improve the intestinal flora of premature infants, promote their growth, or prevent intestinal inflammation.

This invention discloses a traditional Chinese medicine composition for treating ulcerative colitis. The composition is made from the following raw materials: Notopterygium root, Angelica pubescens root, Poria cocos, Saposhnikovia root, Schizonepeta tenuifolia root, Ligusticum chuanxiong rhizome, Platycodon grandiflorus root, Bupleurum chinense root, Peucedanum praeruptorum root, Citrus aurantium fruit, and Glycyrrhiza uralensis root. Animal experiments show that the traditional Chinese medicine composition of this invention significantly alleviates weight loss, reduces diarrhea and bleeding symptoms, lowers the disease activity index, and increases colon length in mice with TNBS or DSS-induced ulcerative colitis, with effects superior to the Schizonepeta tenuifolia and Saposhnikovia root combination. This traditional Chinese medicine composition has significant therapeutic effects on ulcerative colitis, is safe for clinical use, and has a very broad application prospect.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).

The application provides a lactobacillus plantarum DX7 and a method and application thereof for producing indole lactic acid, relates to the field of food microbial technology, and the lactobacillus plantarum DX7 has been preserved in the Guangdong Microbial Culture Collection Center on June 12, 2025, and the preservation number is GDMCC NO.66498. The lactobacillus plantarum DX7 in the application is significantly activated under the stimulation of deep-line walnut inner seed coat polyphenol, and can efficiently convert tryptophan into ILA. Experimental results show that the ILA yield of the strain reaches 217.56 mu g / mL. Moreover, the strain and deep-line walnut inner seed coat polyphenol can significantly relieve the colon inflammation symptoms of a DSS-induced colon inflammation mouse by gavage. The application not only provides a new strategy for efficient biological preparation of the functional component ILA, but also provides a basis and potential solution for dietary intervention of inflammatory bowel disease.

The application discloses application of forskolin and / or isoforskolin in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of medicines.The medicine can significantly improve the disease phenotype of colitis, including relieving weight loss, reducing disease activity index score, improving colon length shortening and histopathological damage.The mechanism of action involves multiple targets: repairing intestinal mucosal barrier function, reducing local inflammation of the colon, and regulating intestinal flora balance, restoring the abundance of beneficial bacteria and inhibiting the proliferation of pathogenic bacteria.The application provides a candidate drug with anti-inflammatory, barrier repair and flora regulation functions for the treatment of colitis, and expands the medical use of forskolin or isoforskolin.

This invention discloses the application of Rehmannia glutinosa exosomes in the preparation of drugs for the prevention of colitis, belonging to the field of plant exosome technology. The Rehmannia glutinosa exosomes extracted using the specific process of this invention not only significantly reduced the DAI score of a colitis model to below 2.0 and restored TNF-α to normal levels, but also unexpectedly improved intestinal motility disorders associated with colitis by bidirectionally regulating gastrointestinal hormones (inhibiting VIP / ET-1 and promoting MTL / SP). This effect is significantly superior to that of traditional water and alcohol extracts of Rehmannia glutinosa.

Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin ανβ6 in a specimen.

A Panax notoginseng polysaccharide iron nanoparticle preparation, its preparation method, and its application are disclosed. This invention can effectively prepare Panax notoginseng polysaccharide iron nanoparticles, solving the application problem in the preparation of drugs for treating iron deficiency anemia, inflammatory bowel disease-related anemia, iron deficiency anemia-related colitis, inflammatory anemia, or inflammatory bowel disease. The specific steps are as follows: The crude Panax notoginseng polysaccharide solution is purified using conventional purification methods to obtain purified Panax notoginseng polysaccharide. This purified polysaccharide is dissolved in ultrapure water, and an iron source is added under inert gas protection. After co-precipitation and chemical reduction reactions, the pH value is adjusted, and iron nanoparticles are loaded onto the Panax notoginseng polysaccharide to obtain Panax notoginseng polysaccharide-coated iron nanoparticles. The preparation method of this invention is simple, uses abundant raw materials, and has low production costs. It represents a major innovation in drugs for treating iron deficiency anemia and inflammatory bowel disease-related iron deficiency anemia, and has practical application value.

This invention belongs to the field of biomedical technology, specifically relating to a fermented product of a traditional Chinese medicine compound for treating colitis, its preparation method, and its application. The fermented product of this traditional Chinese medicine compound for treating colitis is prepared by microbial fermentation of a traditional Chinese medicine compound; the traditional Chinese medicine compound includes Scutellaria baicalensis, malt, Broussonetia papyrifera fruit, mung bean peel, Bletilla striata, Amomum villosum, and Poria cocos; the microorganisms include lactic acid bacteria and yeast. This invention features a scientific and rational formulation, with multiple traditional Chinese medicines working synergistically to target inflammation, repair the intestinal mucosa, and regulate intestinal function, resulting in a more comprehensive treatment effect for colitis, with high safety and definite efficacy; the raw materials used are widely available and inexpensive, resulting in low treatment costs.

The disclosure herein relates to the development and production of novel antibodies and antigen-binding fragments thereof that bind to TL1A and are useful in the treatment, prevention, and diagnosis of diseases, disorders, or inflammation, including, for example, autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis, including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of the final antibody structure are designed de novo by a computer system and its data training set, without reference to a particular reference molecule.

This invention discloses the application of psoralen in the preparation of FFA4 receptor agonists and drugs for FFA4 receptor-related diseases. Cellular experiments show that this compound is a concentration-dependent FFA4 agonist; animal experiments show that this compound has significant efficacy in a DSS-induced colitis model, reducing DSS-induced colonic shortening, improving weight loss, and alleviating splenic swelling. This compound can be used in the preparation of FFA4 agonists and in the prevention and treatment of FFA4-related diseases such as inflammatory bowel disease.

This invention discloses the application of total flavonoids from sea buckthorn leaves in the preparation of drugs for treating ulcerative colitis, relating to the pharmaceutical field. Animal experiments of this invention have demonstrated that total flavonoids from sea buckthorn leaves can effectively alleviate clinical symptoms and pathological damage of ulcerative colitis; improve intestinal barrier damage in mice with ulcerative colitis; improve the inflammatory response in mice with ulcerative colitis; improve the decreased secretion of short-chain fatty acids in mice with ulcerative colitis; and regulate the abundance and structure of intestinal flora in mice with ulcerative colitis. It shows promise for developing new anti-ulcerative colitis drugs. Therefore, sea buckthorn leaves can be transformed from waste into a valuable resource, providing solid preclinical research evidence for the subsequent development of special medical foods, health products, or functional teas with sea buckthorn leaf flavonoids as the core component, offering daily nutritional support and disease management for patients with ulcerative colitis.